Back to top
more

FibroGen (FGEN)

(Delayed Data from NSDQ)

$1.04 USD

1.04
653,315

+0.02 (1.96%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can FibroGen (FGEN) Climb 136% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for FibroGen (FGEN) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study

by Zacks Equity Research

FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.

Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia

by Zacks Equity Research

Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.

FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA

by Zacks Equity Research

NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why FibroGen (FGEN) Might Surprise This Earnings Season

by Zacks Equity Research

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

by Zacks Equity Research

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 13.33% and 1.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Aditi Saraogi headshot

Why Earnings Season Could Be Great for FibroGen (FGEN)

by Aditi Saraogi

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

by Zacks Equity Research

The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.

Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -120.69% and -25.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication

by Zacks Equity Research

FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.

    Benjamin Rains headshot

    Find Strong Stocks with this First Profit Screener

    by Benjamin Rains

    Let's use our 'First Profit' screener to help find stocks that investors might want to consider buying after they posted positive earnings for the first time ever, or for some time...

    FibroGen (FGEN) Q3 Earnings Beat Estimates

    by Zacks Equity Research

    FibroGen (FGEN) delivered earnings and revenue surprises of 139.33% and -10.19%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

    by Zacks Equity Research

    Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.

    FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Theravance Doses First Patient in Phase II Coronavirus Study

    by Zacks Equity Research

    Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

    FibroGen Begins Phase II Study for Acute Coronavirus in US

    by Zacks Equity Research

    FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.

    FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher

    by Zacks Equity Research

    FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    FibroGen Initiates Phase II/III Study in Severe Coronavirus

    by Zacks Equity Research

    FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.